Clinical trials: Renal Dysfunction
End Stage Renal Disease
Testing Tissue Sodium Stores in CAPD Patients-Aims 1 & 2
The investigators' overarching goal is to improve long-term outcomes for end stage renal disease (ESRD) patients. In this study we focus specifically on patients receiving peritoneal dialysis (PD).
- Trial name
- NCT02212327
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Chronic Kidney Diseases, Sarcopenia
Multimorbidity and Sarcopenia Feasibility Study in Chronic Kidney Disease
The aim of this research study is to look at the body composition (such as muscle and fat) in people with chronic kidney disease (CKD) and comparing it with body composition is people without CKD.
- Trial name
- MaSS-CKD (NCT06109662)
- Testing
- Cystatin C eGFR, Bioimpedance Analysis (Body composition analysis)
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency
The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency
The trial was designed in a single dose, open, non-randomized, multi-dose parallel control group. The study of patients were mild and moderate renal insufficiency, and matched healthy subjects.
- Trial name
- RI (NCT06883656)
- Testing
- SAL067
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Renal Impairment
Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment
This is a single dose, non-randomized, open-label, parallel group study. The study will be conducted in participants with severe renal impairment and compared with matched participants with normal renal function.
- Trial name
- NCT04469907
- Testing
- AZD9977
- Where
- 6 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Diabetes
Kidney Check: Diabetes, Blood Pressure & Kidney Health Checks & Care in Indigenous Communities.
Faced with limited access to preventative health care services, Indigenous people living in rural and remote communities are at a higher risk of Chronic Kidney Disease (CKD) and kidney failure, when compared to the general…
- Conditions
- Chronic Kidney Disease, Diabetes, Hypertension
- Trial name
- NCT03595267
- Testing
- Point-of-care screening
- Where
- 3 sites in Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Chronic Kidney Diseases, Obstructive Sleep Apnea
World Trade Center Kidney-Link
This study focuses on the prevalence and identification of kidney disease among participants of the WTC Health Program and the study team are planning to assess kidney disease in a multi-factorial manner.
- Trial name
- NCT03234530
- Where
- United States
- Volunteers
- 555 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Atherosclerosis of Artery, Inflammation
The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
Chronic kidney disease (CKD), is characterized by accelerated development of atherosclerosis and advanced remodelling of vessels and the heart.
- Conditions
- Atherosclerosis of Artery, Inflammation, Chronic Kidney Diseases, Dialysis; Complications
- Trial name
- NCT05214872
- Testing
- laboratory parameters - complete blood count, body mass index (BMI) [kg/m^2] calculation, selected parameters of oxidative stress (1)
- Where
- Poland
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Poznan University of Medical Sciences
Primary Hypertension, Secondary Hypertension
HaemoDYNAMICs in Primary and Secondary Hypertension
The primary aim of the present study was to examine the haemodynamic changes in primary hypertension and secondary hypertension (renal diseases, endocrine diseases, obesity-associated hypertension) with a non-invasive…
- Conditions
- Primary Hypertension, Secondary Hypertension, Aortic Stenosis, Renal Insufficiency
- Trial name
- DYNAMIC (NCT01742702)
- Testing
- Nitroglycerin 0.25 mg (single dose, no longer given since January 2017), Salbutamol 400 µg (single dose, no longer given since January 2017), L-arginine (10 min infusion, no longer given since January 2017)
- Where
- 2 sites in Finland
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Tampere University
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and…
- Conditions
- Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm
- Trial name
- NCT06741072
- Testing
- Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hypertension, Coronary Disease
Analyzing How Genetics May Affect Response to High Blood Pressure Medications
High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications.
- Conditions
- Hypertension, Coronary Disease, Cerebrovascular Accident
- Trial name
- NCT00563901
- Where
- 2 sites in United States
- Volunteers
- 37,939 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Hepatitis B
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood.
- Trial name
- B-Kind (NCT07168356)
- Testing
- Bepirovirsen
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Kidney Injury, Kidney Ischemia
FGF23 as a Marker of Acute Kidney Injury
A partial nephrectomy (PN) preserves renal parenchyma with a proper oncology outcome. PN is performed during transitory ischemia to avoid massive bleeding during tumor resection.
- Trial name
- NCT04693962
- Testing
- Plasmatic Fibroblast Growth Factor-23 by means of ELISA
- Where
- Chile
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Chile
Chronic Kidney Diseases
SOP's for CKD-MBD-Biomarkers
CKD-MBD (Chronic Kidney Disease - Mineral and Bone Disorder) is an extensive disease and includes dysfunction of the mineral metabolism, the bone metabolism and cardiovascular diseases in the context of renal insufficiency.
- Trial name
- NCT02708368
- Testing
- blood withdrawal
- Where
- 2 sites in Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Uterine Fibroids, Endometriosis
Pharmacokinetics and Safety of Vilaprisan in Renal Impairment
The purpose of the study is to evaluate the pharmacokinetics of vilaprisan in subjects with moderate to severe renal impairment compared with matched subjects with normal renal function.
- Trial name
- NCT03411980
- Testing
- Vilaprisan (BAY1002670)
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Renal Impairment in Type 2 Diabetic Subjects
The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with…
- Trial name
- NCT00554450
- Testing
- Dapagliflozin
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction
A randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and the impact of food on pharmacokinetics of oral HS-10398 in Chinese healthy…
- Trial name
- NCT06383897
- Testing
- HS-10398
- Where
- China
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetic Nephropathy, Endothelial Dysfunction
Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes
Diabetes is the most common metabolic disease of childhood. Vascular disease is a leading complication of diabetes, and attempts to maintain close glycemic control do not prevent the sequelae that claim the lives and quality of…
- Trial name
- flavonoid (NCT01307917)
- Testing
- flavonoids
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Renal Dialysis
Pain Perception by the Chronic Renal Patient at the Time of Vascular Access Cannulation.
Pain in patients under hemodialysis affects chronic renal patients' quality of life. Distraction has been effective in controlling pain induced by the insertion of needles.
- Trial name
- NCT05729113
- Testing
- Distraction technique
- Where
- Portugal
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Joana Sofia Dias Pereira de Sousa
Renal Impairment
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
The purpose of this study is to characterize the effect of renal function on the PK of a 0.25 mg single oral dose of bevenopran in humans and to assess the safety and tolerability of bevenopran in patients with varying degrees of…
- Trial name
- NCT02508740
- Testing
- bevenopran
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Renal Failure, Chronic, End-Stage Renal Disease
PK of Serelaxin in Severe Renal Impairment and ESRD
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD)…
- Trial name
- CRLX030A2102 (NCT01875523)
- Testing
- Serelaxin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.